Neglected Tropical Disease Treatment Market Size & Growth Forecast 2027–2036, By Segments (Product, Disease), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Neglected Tropical Disease Treatment Market size was over USD 4.22 billion in 2026 and is likely to grow at a 5.18% CAGR between 2027 and 2036, exceeding USD 6.99 billion by 2036. The industry revenue for 2027 is estimated at USD 4.4 billion.
Get more details on this report
Request Free Sample ReportNeglected Tropical Disease Treatment Market Intelligence Snapshot
Regional Market Dynamics
- North America benefits from strong pharmaceutical research capabilities, established infectious disease surveillance, clinical research networks, and advanced healthcare systems supporting the development and availability of specialized treatments.
- Asia Pacific is growing fastest due to the continued disease burden, expanding healthcare infrastructure, government-led disease control programs, and increasing investment in diagnosis, treatment access, and community-level healthcare delivery.
Segment Momentum
- Drugs accounted for 66.37% of the product segment in 2026 and are also its fastest-growing category, supported by their essential role in community-based treatment programs, primary healthcare delivery, and efforts to expand access to essential medicines.
- Dengue accounted for 12.51% of the disease segment in 2026 and is also the fastest-growing category, supported by persistent transmission, recurring treatment needs, and public health efforts focused on early diagnosis and outbreak management.
Market Expansion Drivers
- Global initiatives to eliminate neglected tropical diseases.
- Development of effective treatments and therapeutics.
- Expansion of healthcare access and treatment distribution in endemic regions.
Leading Market Participants
- Key companies in the neglected tropical disease treatment market include GlaxoSmithKline (UK), Merck (USA), Pfizer (USA), Sanofi (France), Johnson & Johnson (USA), Novartis (Switzerland), Bayer (Germany), Takeda (Japan), Eisai (Japan), AbbVie (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.22 billion
- 2027 Estimated Market Size: USD 4.4 billion
- Projected Market Size: USD 6.99 billion by 2036
- Growth Forecast: 5.18% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Product (Drugs) | Disease (Dengue)
- Emerging Opportunity Segment: Product (Drugs) | Disease (Dengue)
Market Growth Drivers and Industry Trends
Global initiatives to eliminate neglected tropical diseases
Global initiatives focused on eliminating neglected tropical diseases are driving demand for diagnosis, prevention, and treatment solutions across endemic regions. International health programs increasingly emphasize integrated disease control, early detection, mass treatment campaigns, and sustained surveillance to reduce transmission and prevent long-term complications. These initiatives are also encouraging greater coordination among governments, healthcare providers, public health organizations, and development agencies, strengthening the implementation of treatment programs. Continued prioritization of neglected tropical diseases within global health agendas is expected to support investment in therapeutic development and expand the adoption of available treatment options.
Development of effective treatments and therapeutics
The development of more effective treatments and therapeutics is supporting growth in the neglected tropical disease treatment market by addressing limitations associated with existing therapies, including prolonged treatment regimens, adverse effects, and inadequate efficacy for certain disease stages. Advances in drug discovery, formulation technologies, combination therapies, and targeted treatment approaches are improving the ability to manage infections and reduce disease-related complications. Increasing research activity is also encouraging the development of therapies that are easier to administer and better suited to resource-limited settings. These advancements are expected to strengthen treatment outcomes and broaden access to effective therapeutic options.
Expansion of healthcare access and treatment distribution in endemic regions
Expansion of healthcare access and treatment distribution in endemic regions is increasing the reach of neglected tropical disease therapies among underserved populations. Improvements in primary healthcare infrastructure, community-based health services, diagnostic capacity, and medicine distribution networks are helping identify affected populations and connect them with appropriate treatment. Strengthening supply chains and decentralized healthcare delivery is particularly important in rural and remote areas where access to specialized medical facilities remains limited. Continued expansion of these healthcare networks is expected to improve treatment coverage, support earlier intervention, and increase demand for neglected tropical disease therapeutics.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Global initiatives to eliminate neglected tropical diseases | 2% | Short term (≤ 2 yrs) | Asia Pacific; Africa; Spillover: Latin America | High | Fast |
| Development of effective treatments and therapeutics | 1.5% | Medium term (2–5 yrs) | North America; Europe; Spillover: Asia Pacific | High | Moderate |
| Expansion of healthcare access and treatment distribution in endemic regions | 1% | Long term (5+ yrs) | Asia Pacific; Africa; Latin America | Medium | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held the largest share in the market in 2026, supported by advanced healthcare infrastructure, strong research capabilities, and established systems for diagnosing and treating infectious and tropical diseases. The region benefits from extensive investment in pharmaceutical research, infectious disease surveillance, and development of innovative therapeutic approaches, supporting the availability of treatments for neglected tropical diseases. Growing emphasis on disease prevention, early diagnosis, and improved access to specialized healthcare is further strengthening treatment demand. In addition, well-developed clinical research networks and collaborations across healthcare and research institutions are supporting the evaluation and advancement of new treatment approaches. The presence of robust regulatory and healthcare systems also facilitates the development and adoption of therapies targeting infectious diseases with significant unmet medical needs. Furthermore, increasing awareness of the global burden of neglected tropical diseases is encouraging continued research and healthcare initiatives focused on improving treatment accessibility.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing region, driven by the continued burden of neglected tropical diseases, expanding healthcare infrastructure, and increasing government attention toward infectious disease control. Large populations in tropical and subtropical areas create substantial demand for accessible diagnosis and treatment solutions. Improvements in healthcare delivery systems and disease surveillance are supporting earlier identification and management of affected populations. In addition, public health programs focused on disease elimination, prevention, and community-level treatment are strengthening access to therapies. Growing investments in healthcare infrastructure and increasing collaboration between governments, research institutions, and international health organizations are further supporting market development. Moreover, rising awareness of neglected tropical diseases and improving availability of diagnostic and treatment services are encouraging broader disease management efforts across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Specialized Treatment AccessThe U.S. market emphasizes access to specialized therapies for neglected tropical diseases through public-health programs, travel medicine, and infectious-disease care. Priorities include maintaining treatment availability, supporting diagnosis of imported cases, and strengthening supply channels for therapies addressing uncommon but clinically significant infections.
Germany 🇩🇪
Public-Health Treatment ReadinessGermany’s neglected tropical disease treatment market is supported by infectious-disease surveillance and access to specialized medicines for imported or travel-associated cases. Priorities include reliable diagnosis, treatment preparedness, specialist expertise, and coordination between public-health services and clinical care.
Japan 🇯🇵
Imported Disease PreparednessJapan’s market places emphasis on diagnosis and treatment preparedness for neglected tropical diseases encountered through travel and international exposure. Priorities include specialist clinical capacity, dependable access to appropriate medicines, and improved recognition of infections that may initially present outside conventional tropical-disease settings.
South Korea 🇰🇷
Tropical Disease Response CapacitySouth Korea’s neglected tropical disease treatment priorities center on strengthening clinical recognition and access to appropriate therapies for imported and travel-associated infections. Hospitals and public-health stakeholders benefit from specialized diagnostic expertise, treatment readiness, and coordinated surveillance for less routinely encountered diseases.
France 🇫🇷
Tropical Medicine ExpertiseFrance maintains strong relevance to neglected tropical disease treatment through specialist infectious-disease and tropical-medicine capabilities. Priorities include timely diagnosis, access to appropriate therapies, surveillance of imported infections, and clinical readiness across healthcare settings connected to international travel and overseas exposure.
Italy 🇮🇹
Travel-Linked Treatment ReadinessItaly’s market is shaped by the need to diagnose and treat neglected tropical diseases associated with international travel and migration. Priorities include specialist infectious-disease services, medicine availability, laboratory confirmation, and improved clinical recognition of conditions that are uncommon in routine domestic practice.
Neglected Tropical Disease Treatment Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Drugs (Largest & Fastest-Growing Segment)
The drugs segment accounted for a 66.37% share of the product segment in 2026, reflecting the central role of pharmaceutical therapies in managing and controlling neglected tropical diseases across endemic and vulnerable populations. Drug-based treatments remain essential because they can be deployed through community-based programs, primary healthcare systems, and disease-control initiatives, supporting broad access in areas where specialized medical infrastructure may be limited. Continued efforts to improve disease detection, expand treatment coverage, and reduce the burden of infectious diseases are sustaining demand for effective therapeutic options. Growing public health attention toward neglected tropical diseases is also encouraging investment in treatment development, formulation improvements, and broader availability of essential medicines. The need for accessible therapies that can be administered efficiently across diverse healthcare settings is expected to support continued adoption of drugs, positioning the segment as both the largest and fastest-growing product category in the market.
Disease Segment Analysis: Dengue (Largest & Fastest-Growing Segment)
The dengue segment held a 12.51% share of the disease segment in 2026, supported by the persistent burden of dengue infections across tropical and subtropical regions and the recurring need for effective disease management. Increasing urbanization, favorable conditions for mosquito proliferation, and changing environmental patterns can contribute to continued transmission, creating sustained demand for treatment and supportive care. Growing awareness of dengue prevention and early diagnosis is also strengthening the need for accessible treatment options, particularly in regions where seasonal outbreaks place additional pressure on healthcare systems. Public health programs focused on vector control, surveillance, and timely clinical management further contribute to market demand by improving recognition and treatment of infections. As dengue continues to represent an important infectious disease challenge, ongoing efforts to expand healthcare access and strengthen outbreak preparedness are supporting its position as both the largest and fastest-growing disease segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Drugs, Vaccines | Drugs | Drugs |
| Disease | Dengue, Rabies, Trachoma, Buruli Ulcer, Yaws, Leprosy, Chagas Disease, Human African Trypanosomiasis (Sleeping Sickness), Leishmaniases, Soil-transmitted Helminthiases, Others | Dengue | Dengue |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Scaling global coverage in the neglected tropical disease market demands that drug developers look beyond core therapeutic efficacy to master field-level usability and public-health distribution realities. Broad-spectrum, multi-parasitic efficacy provides strategic leverage in low-diagnostic regions, yet practical adoption depends equally on formulation engineering—specifically heat-stable compositions and child-friendly dosing that thrive outside rigid cold-chain networks. Sustainable market penetration relies on aligning pharmaceutical innovation with public-private procurement frameworks, where volume-based supply commitments, tiered pricing models, and dependable last-mile logistics dictate whether critical therapies effectively reach vulnerable, endemic populations.
Major players in the neglected tropical disease treatment market:
- GlaxoSmithKline (UK)
- Merck (USA)
- Pfizer (USA)
- Sanofi (France)
- Johnson & Johnson (USA)
- Novartis (Switzerland)
- Bayer (Germany)
- Takeda (Japan)
- Eisai (Japan)
- AbbVie (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline (UK) | |||||||
| Merck (USA) | |||||||
| Pfizer (USA) | |||||||
| Sanofi (France) | |||||||
| Johnson & Johnson (USA) | |||||||
| Novartis (Switzerland) | |||||||
| Bayer (Germany) | |||||||
| Takeda (Japan) | |||||||
| Eisai (Japan) | |||||||
| AbbVie (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Novartis | July 2025 | Novartis received Swissmedic approval for Coartem Baby, the first antimalarial medication specifically formulated for newborns and infants weighing under five kilograms. Developed in collaboration with Medicines for Malaria Venture, the treatment addresses a critical pediatric care gap in malaria-endemic regions by accommodating infant metabolic differences. |
| World Health Organization | May 2024 | The World Health Organization and the Global Health Innovative Technology Fund formalized a partnership to expand access to affordable drugs, vaccines, and diagnostics for neglected tropical diseases. The collaboration prioritizes accelerating the development and distribution of essential therapeutic interventions across low-income and remote regions. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Neglected Tropical Disease Treatment Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Route of Administration | Oral, Injectable, Topical, Other Routes |
| Treatment Setting | Hospitals & Specialty Clinics, Primary Healthcare Centers, Community-Based Programs, Public Health & Mass Drug Administration Programs |
| Access Model | Commercial Procurement, Government Procurement, International Aid & Donor Programs, Public-Private Partnerships |
Neglected Tropical Disease Treatment Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Disease Elimination Pathways |
|
| Treatment Access & Affordability |
|
| Clinical Pipeline & Unmet Needs |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the estimated worth of the neglected tropical disease treatment market?
How much is the neglected tropical disease treatment industry expected to grow by 2036?
How are global disease-elimination initiatives influencing demand for neglected tropical disease treatments?
How is healthcare access expansion improving the reach of neglected tropical disease therapies?
Why do drugs dominate the neglected tropical disease treatment market?
Why is dengue an important segment in the neglected tropical disease treatment market?
Why does North America hold the largest share of the neglected tropical disease treatment market?
What is driving neglected tropical disease treatment market growth in Asia Pacific?
Who are the major participants shaping the neglected tropical disease treatment landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook